

CME MONOGRAPH

THE ROLE OF NITRIC OXIDE IN GLAUCOMA

FACULTY


LOUIS R. PASQUALE, MD (CHAIR)

EMMANUEL S. BUYS, PHD

PAUL L. KAUFMAN, MD

W. DANIEL STAMER, PHD

ROBERT N. WEINREB, MD



ORIGINAL RELEASE:
AUGUST 1, 2016

LAST REVIEW:
JULY 5, 2016

EXPIRATION:
AUGUST 31, 2017

Visit <http://tinyurl.com/nitricoxidelOP> for online testing and instant CME certificate.



New York
Eye and Ear
Infirmary of
Mount
Sinai

MedEdicus
LLC

This continuing medical education activity is jointly provided by
New York Eye and Ear Infirmary of Mount Sinai and MedEdicus LLC.

Distributed with EyeNet

This continuing medical education activity is supported through
an unrestricted educational grant from Bausch & Lomb Incorporated.

LEARNING METHOD AND MEDIUM

This educational activity consists of a supplement and seven (7) study questions. The participant should, in order, read the learning objectives contained at the beginning of this supplement, read the supplement, answer all questions in the post test, and complete the Activity Evaluation/Credit Request form. To receive credit for this activity, please follow the instructions provided on the post test and Activity Evaluation/Credit Request form. This educational activity should take a maximum of 1.5 hours to complete.

CONTENT SOURCE

This continuing medical education (CME) activity captures content from an expert roundtable discussion.

ACTIVITY DESCRIPTION

Primary open-angle glaucoma is a leading cause of blindness, and although advances in pharmacologic and surgical treatments for glaucoma continue to grow, patients with glaucoma are still at risk for vision loss and blindness. Unfortunately, treatments to directly protect retinal ganglion cells from degeneration—the ultimate cause of vision loss—are lacking. New drugs, new fixed combinations of existing drugs, and new procedures constantly challenge the traditional treatment paradigm and are showing promise in lowering intraocular pressure (IOP) and slowing disease progression by multiple mechanisms of action. One explored mechanism involves nitric oxide signaling, which has been shown to have a role in the regulation of IOP. The purpose of this activity is to update ophthalmologists on the role of nitric oxide in the etiology and management of glaucoma.

TARGET AUDIENCE

This educational activity is intended for ophthalmologists.

LEARNING OBJECTIVES

Upon completion of this activity, participants will be better able to:

- Correlate the pathophysiologic factors contributing to glaucoma with sites of action for available treatments
- Discuss the role of nitric oxide in IOP regulation
- Describe the potential role of nitric oxide–based emerging therapeutics in the management of glaucoma

ACCREDITATION STATEMENT

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of **New York Eye and Ear Infirmary of Mount Sinai** and MedEdicus LLC. The **New York Eye and Ear Infirmary of Mount Sinai** is accredited by the ACCME to provide continuing medical education for physicians.



In July 2013, the Accreditation Council for Continuing Medical Education (ACCME) awarded New York Eye and Ear Infirmary of Mount Sinai "Accreditation with Commendation," for six years as a provider of continuing medical education for physicians, the highest accreditation status awarded by the ACCME.

AMA CREDIT DESIGNATION STATEMENT

The **New York Eye and Ear Infirmary of Mount Sinai** designates this enduring material for a maximum of 1.5 **AMA PRA Category 1 Credits™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

GRANTOR STATEMENT

This continuing medical education activity is supported through an unrestricted educational grant from Bausch & Lomb Incorporated.

DISCLOSURE POLICY STATEMENT

It is the policy of **New York Eye and Ear Infirmary of Mount Sinai** that the faculty and anyone in a position to

control activity content disclose any real or apparent conflicts of interest relating to the topics of this educational activity, and also disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentation(s). **New York Eye and Ear Infirmary of Mount Sinai** has established policies in place that will identify and resolve all conflicts of interest prior to this educational activity. Full disclosure of faculty/planners and their commercial relationships, if any, follows.

DISCLOSURES

Emmanuel S. Buys, PhD, had a financial agreement or affiliation during the past year with the following commercial interest in the form of *Consultant/Advisory Board*: Bausch & Lomb Incorporated.

Paul L. Kaufman, MD, had a financial agreement or affiliation during the past year with the following commercial interest in the form of *Consultant/Advisory Board*: AGTC; Alcon; Allergan; Amakem Therapeutics; Bausch & Lomb Incorporated; Refocus Group, Inc; Sucampo Pharmaceuticals, Inc; and Valeant; *Contracted Research*: LENSAR, Inc; ReGen Eye; Vista Ocular; and Z Lens LLC; *Honoraria from promotional, advertising or non-CME services received directly from commercial interests or their Agents (eg, Speakers Bureaus)*: AGTC; Alcon; Allergan; Amakem Therapeutics; Bausch & Lomb Incorporated; Refocus Group, Inc; Sucampo Pharmaceuticals, Inc; and Valeant; *Other (Travel)*: Alcon.

Louis R. Pasquale, MD, had a financial agreement or affiliation during the past year with the following commercial interests in the form of *Consultant/Advisory Board*: Bausch & Lomb Incorporated; and Novartis AG; *Honoraria from promotional, advertising or non-CME services received directly from commercial interests or their Agents (eg, Speakers Bureaus)*: Allergan; *Other (Travel)*: Aerie Pharmaceuticals, Inc; and Glaukos Corporation.

W. Daniel Stamer, PhD, had a financial agreement or affiliation during the past year with the following commercial interests in the form of *Consultant/Advisory Board*: Aerie Pharmaceuticals, Inc; Bausch & Lomb Incorporated; and Nicox; *Contracted Research*: Aerie Pharmaceuticals, Inc; Allergan; Inotek Pharmaceuticals Corporation; Ironwood Pharmaceuticals, Inc; and Novartis AG.

Robert N. Weinreb, MD, had a financial agreement or affiliation during the past year with the following commercial interests in the form of *Consultant/Advisory Board*: Aerie Pharmaceuticals, Inc; Alcon; Allergan; Bausch & Lomb Incorporated; ForSight VISION5; Nemus Bioscience, Inc; Unity; and Valeant; *Contracted Research*: Genentech, Inc; and Quark.

NEW YORK EYE AND EAR INFIRMARY OF MOUNT SINAI PEER REVIEW DISCLOSURE

Joseph F. Panarelli, MD, has no relevant commercial relationships to disclose.

EDITORIAL SUPPORT DISCLOSURES

Tony Realini, MD, had a financial agreement or affiliation during the past year with the following commercial interests in the form of *Consultant/Advisory Board*: Alcon; Alimera Sciences; Bausch & Lomb Incorporated; Inotek Pharmaceuticals Corporation; and Reichert, Inc; *Contracted Research*: Alcon; *Honoraria from promotional, advertising or non-CME services received directly from commercial interests or their Agents (eg, Speakers Bureaus)*: Lumenis.

Diane McArdle, PhD; **Cynthia Tornallyay, RD, MBA, CHCP**; **Kimberly Corbin, CHCP**; **Barbara Aubel**; and **Michelle Ong** have no relevant commercial relationships to disclose.

DISCLOSURE ATTESTATION

The contributing physicians listed above have attested to the following:

- 1) that the relationships/affiliations noted will not bias or otherwise influence their involvement in this activity;
- 2) that practice recommendations given relevant to the companies with whom they have relationships/affiliations will be supported by the best available evidence or, absent evidence, will be consistent with generally accepted medical practice; and
- 3) that all reasonable clinical alternatives will be discussed when making practice recommendations.

OFF-LABEL DISCUSSION

This CME activity includes discussion of unlabeled and/or investigative uses of drugs. Please refer to the official prescribing information for each drug discussed in this activity for FDA-approved dosing, indications, and warnings.

For Digital Editions

System Requirements:

If you are viewing this activity online, please ensure the computer you are using meets the following requirements:

- **Operating System:** Windows or Macintosh
- **Media Viewing Requirements:** Flash Player or Adobe Reader
- **Supported Browsers:** Microsoft Internet Explorer, Firefox, Google Chrome, Safari, and Opera
- **A good Internet connection**

New York Eye and Ear Infirmary of Mount Sinai Privacy & Confidentiality Policies

<http://www.nyee.edu/health-professionals/cme/enduring-activities>

CME Provider Contact Information

For questions about this activity, call 212-979-4383.

TO OBTAIN AMA PRA CATEGORY 1 CREDIT™

To obtain **AMA PRA Category 1 Credit™** for this activity, read the material in its entirety and consult referenced sources as necessary. Complete the evaluation form along with the post test answer box within this supplement. Remove the Activity Evaluation/Credit Request page from the printed supplement or print the Activity Evaluation/Credit Request page from the Digital Edition. Return via mail to Kim Corbin, Director, ICME, **New York Eye and Ear Infirmary of Mount Sinai**, 310 East 14th Street, New York, NY 10003 or fax to (212) 353-5703. Your certificate will be mailed to the address you provide on the Activity Evaluation/Credit Request form. Please allow 3 weeks for Activity Evaluation/Credit Request forms to be processed. There are no fees for participating in and receiving CME credit for this activity.

Alternatively, we offer instant certificate processing and support Green CME. Please take this post test and evaluation online by going to <http://tinyurl.com/nitricoxidelOP>. Upon passing, you will receive your certificate immediately. You must score 70% or higher to receive credit for this activity, and may take the test up to 2 times. Upon registering and successfully completing the post test, your certificate will be made available online and you can print it or file it.

DISCLAIMER

The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of **New York Eye and Ear Infirmary of Mount Sinai**, MedEdicus LLC, Bausch & Lomb Incorporated, *EyeNet*, or American Academy of Ophthalmology.

PROGRAM CHAIR

LOUIS R. PASQUALE, MD

Professor of Ophthalmology
Harvard Medical School
Director, Glaucoma Service
Massachusetts Eye and Ear
Boston, Massachusetts

FACULTY

EMMANUEL S. BUYS, PhD

Associate Professor of Anesthesia
Associate Professor of Ophthalmology
Associate Investigator
Department of Anesthesia, Critical Care,
and Pain Medicine
Massachusetts General Hospital Research Institute
Boston, Massachusetts

PAUL L. KAUFMAN, MD

Ernst H. Bárány Professor of Ocular Pharmacology
Department Chair Emeritus
Department of Ophthalmology and Visual Sciences
University of Wisconsin
Madison, Wisconsin

W. DANIEL STAMER, PhD

Joseph A. C. Wadsworth Professor of Ophthalmology
Professor of Biomedical Engineering
Duke University School of Medicine
Durham, North Carolina

ROBERT N. WEINREB, MD

Chairman and Distinguished Professor
of Ophthalmology
Director, Shiley Eye Institute
Director, Hamilton Glaucoma Center
Morris Gleich MD Chair of Glaucoma
University of California, San Diego
San Diego, California

CME REVIEWER FOR NEW YORK EYE AND EAR INFIRMARY OF MOUNT SINAI

JOSEPH F. PANARELLI, MD

Assistant Professor of Ophthalmology
Icahn School of Medicine of Mount Sinai
Associate Residency Program Director
New York Eye and Ear Infirmary of Mount Sinai
New York, New York

THE ROLE OF NITRIC OXIDE IN GLAUCOMA

INTRODUCTION

Currently, we have several therapies to lower intraocular pressure (IOP) and prevent progression and vision loss from glaucoma. The availability of highly effective medications with excellent safety profiles and convenient dosing permits the development of treatment regimens that are personalized to the needs and desires of each individual patient with this disease. Despite these therapeutic options, some people with glaucoma continue to develop visual loss and dysfunction attributable to the disease. The role of nitric oxide (NO) and its metabolic pathway as potential new therapeutic targets for glaucoma are described herein.

HISTORY OF NITRIC OXIDE AND ITS ROLES IN HUMAN PHYSIOLOGY

Joseph Priestley first discovered NO in the 1770s,¹ and for the next 200 years, it was generally considered a toxic gas and air pollutant and disregarded with respect to human health. Over these next 2 centuries, several observations challenged this perception. The first was the use of nitroglycerin to relieve angina pectoris. The second was in the explosives industry, in which workers chronically exposed to nitroglycerin in the manufacture of trinitrotoluene developed short-term tolerance to nitrate-mediated vasodilation that wore off over the weekend, producing acute effects of tachycardia, dizziness, and headache from vasodilation upon reexposure. This constellation of symptoms was referred to as “Monday disease.” More recently, in 1977, NO was identified as an important component in the mechanism of action of nitrates in producing vasodilation, which explained its beneficial role in managing angina pectoris and shed light on the pathophysiology of Monday disease.^{2,3} A decade later, in 1987, endogenous NO synthesis was demonstrated

Cover photograph courtesy of Murray Fingeret, OD.

This CME activity is copyrighted to MedEdicus LLC ©2016. All rights reserved.

Sponsored Supplement

in endothelial cells⁴; thereafter, NO was rapidly recognized to have important regulatory roles in many biologic systems, including the cardiovascular and neurologic systems. Just 5 years later, the American Association for the Advancement of Science (publishers of *Science*) named NO the 1992 “Molecule of the Year.”⁵ The research that promoted this molecule from pollutant to Molecule of the Year in 15 short years earned 3 scientists the 1998 Nobel Prize in Medicine to honor their work in demonstrating NO’s role as a signaling molecule in the cardiovascular system.

Nitric oxide is synthesized by nitric oxide synthase (NOS), a cytochrome P-450 enzyme. There are 2 constitutive isoforms (neuronal NOS1 and endothelial NOS3) and an inducible isoform (NOS2).⁶ These isoforms are encoded by 3 different genes, each located on a different chromosome. Nitric oxide synthase produces NO in 2 steps by oxidizing L-arginine to L-hydroxyarginine and then to NO and citrulline.

Once synthesized, NO activates soluble guanylate cyclase (sGC), which then converts guanosine triphosphate to cyclic guanosine monophosphate (cGMP). cGMP is a second messenger (much like cyclic adenosine monophosphate) that modulates smooth muscle relaxation and vasodilation and many important biologic processes, such as platelet inhibition and cell growth and differentiation (**Figure 1**).⁶




Figure 1. Nitric oxide metabolic pathway and its physiologic effects.⁶ Intracellular nitric oxide, synthesized by endothelial nitric oxide synthase, catalyzes the conversion of GTP to cGMP by guanylate cyclase. cGMP is a second messenger that signals a variety of downstream actions that leads to smooth muscle relaxation, inhibition of platelet adhesion/aggregation, and promotion of cell growth and differentiation. Reduction of cGMP levels can result in disease states related to the disruption of hemostasis.

Abbreviations: cGMP, cyclic guanosine monophosphate; eNOS, endothelial nitric oxide synthase; GTP, guanosine triphosphate.

NITRIC OXIDE IN NONOCULAR PATHOPHYSIOLOGY

Reduction of cGMP by inhibition of NO signaling plays a causal role in many human diseases and disorders related to vasoconstriction and/or vasospasm. These include angina pectoris, pulmonary hypertension, erectile dysfunction, thrombosis, and atherosclerosis.⁶ Strategies to increase cGMP levels have yielded numerous important treatments for diseases and disorders involving the NO pathway (**Figure 2**). Among these are the phosphodiesterase (PDE) inhibitors, which increase cGMP levels in cells by blocking its degradation. The resulting pharmacodynamic effect is smooth muscle relaxation. Phosphodiesterase inhibitors are commonly used to treat erectile dysfunction, in which they induce local vasodilation that in turn increases the blood supply to the penis.⁷ Other PDE inhibitors, such as roflumilast and cilomilast, and nonspecific PDE inhibitors, such as theophylline and theobromine, produce bronchodilation in the treatment of asthma.⁸ In addition, the sGC activator riociguat is approved for use in the management of pulmonary arterial hypertension.⁹ Other potential applications may include myocardial failure and endotoxic shock.¹⁰




Figure 2. Pharmacologic targets in the nitric oxide pathway. The nitric oxide pathway has several actionable targets for pharmacologic management of disease states resulting from reduction in cGMP through various mechanisms. These include agents that increase endogenous levels of nitric oxide (LBN/glaucoma [experimental]), activate guanylate cyclase (riociguat/pulmonary hypertension), and increase cGMP levels by inhibiting PDE5 (sildenafil/erectile dysfunction).

Abbreviations: ADP, adenosine diphosphate; ARG, arginine; ATP, adenosine triphosphate; cGMP, cyclic guanosine monophosphate; eNOS, endothelial nitric oxide synthase; GC, guanylate cyclase; GMP, guanosine monophosphate; GTP, guanosine triphosphate; LBN, latanoprostene bunod; NO, nitric oxide; P, phosphate; PDE5, phosphodiesterase type 5; PKG, protein kinase G.

NITRIC OXIDE IN THE HEALTHY EYE

Nitric oxide has important physiologic effects in the tissues that regulate both IOP and optic nerve head blood flow and plays an important physiologic role in the regulation of both of these dynamic parameters.

The optic nerve has a complex blood supply fed by 4 distinct circulatory beds, including the ophthalmic and posterior ciliary arteries as well as both the choroidal and retinal vascular beds. In the optic nerve head, NO donors decrease vascular resistance by relaxing smooth muscle, resulting in local vasodilation and increased optic nerve head blood flow.^{10,11} Conversely, impairment of the NO pathway reduces optic nerve blood flow, resulting in ischemia.^{12,13}

In a healthy eye, IOP is determined by the balance between aqueous humor production and outflow. Aqueous humor is produced by the nonpigmented epithelial cells of the ciliary body. Aqueous humor egress from the eye occurs via 2 distinct pathways: uveoscleral and canalicular. The uveoscleral outflow pathway is incompletely understood and involves passage of aqueous humor through the anterior uveal tract via the extracellular matrix-filled space between the ciliary muscle bundles into the suprachoroidal space, which then exits the eye via several routes, including choroidal veins and ocular lymphatics, as well as through the sclera. The canalicular pathway refers to the movement of aqueous humor through the trabecular meshwork (TM) to the Schlemm canal, with subsequent entry into the episcleral circulation. The TM is composed of extracellular matrix beams lined with trabecular cells. Like vascular smooth muscle cells, trabecular cells are contractile in nature.¹⁴ Trabecular cell contraction involves the interaction of actin and myosin and results in dense packing of the TM tissue, which reduces aqueous outflow. Resistance to outflow through the TM and inner wall of the Schlemm canal is the primary determinant of IOP. The beam cells of the inner TM are less important than the juxtacanalicular cells of the outer TM in regulating resistance to outflow.

Nitric oxide has important physiologic effects in several of the tissues relevant to the maintenance of IOP. Evidence for the role of NO in IOP regulation comes from several lines of research. Importantly, NOS3 is present in the uveal vascular endothelium, Schlemm canal, and ciliary body.^{15,16} Nitric oxide is known to increase trabecular outflow facility

in the human anterior segment,¹⁷ and NO donors lower IOP in animal models.¹⁸ cGMP also increases outflow facility in live monkey eyes.¹⁹ Further, mice overexpressing NOS3 have lower IOP.²⁰ NOS3 knockout mice (animals with no functional NOS3 gene and thus no endogenous NOS3) have elevated IOP,²¹ and sGC knockout mice exhibit both elevated IOP and optic nerve degeneration.²² The mechanism by which NO lowers IOP is via inhibition of actin-myosin interactions, which leads to relaxation of cells in the TM and Schlemm canal and subsequent enhanced aqueous outflow and IOP reduction.^{23,24}

NITRIC OXIDE IN THE GLAUCOMATOUS EYE

There is significant evidence that NO pathway dysfunction plays a causal role in the pathophysiology of primary open-angle glaucoma (POAG). In the optic nerve head, the NO system promotes vasodilation and increased blood flow to this important tissue bed. Conversely, inhibition of the NO pathway would be expected to reduce optic nerve head blood flow.

Evidence for these hypotheses in humans has been reported. In a clinical trial involving 12 patients with glaucoma and 12 healthy subjects, NOS inhibition accomplished by intravenous administration of a known inhibitor of NOS reduced optic nerve head blood flow in healthy eyes more than in glaucomatous eyes ($P = .03$),²⁵ suggesting that the NO pathway is already impaired in glaucomatous eyes.

Support for the role of NO pathway impairment in IOP regulation comes from several distinct lines of research. L-arginine levels are high in the aqueous humor of patients with glaucoma²⁶ and in the vitreous humor of monkeys with experimental glaucoma.²⁷ Further, NO levels are low in the aqueous humor of patients with glaucoma.^{28,29} Additionally, NOS3 gene variants have been described in relation to POAG in many studies.³⁰⁻³²

Other data support a role for impaired NO signaling in the pathophysiology of glaucoma. Acetylcholine (ACh) is known to mediate vasodilation via the generation of NO. Therefore, ACh delivered to healthy subjects would be expected to increase blood flow via NO signaling, whereas a reduced or absent increase in blood flow would be expected in subjects with impairment of the NO signaling pathway. In a pharmacologic intervention study, an

CLINICAL RELEVANCE

EXPERT COMMENTARY

Q: Is the nitric oxide signaling pathway a potential therapeutic target for glaucoma?

Dr Pasquale: Nitric oxide represents a novel therapeutic target in glaucoma management. The considerable evidence that ocular vessels in glaucomatous eyes are dysregulated in response to physiologic perturbations suggests impaired NO signaling is present in POAG. In fact, this dysregulation involves nonocular vascular beds as well.

Dr Stamer: Discrepancies between the efficacy of NO-donating compounds in preclinical studies and clinical trials is likely because of delivery of NO deep into the TM, where outflow resistance is controlled.

Dr Pasquale: Furthermore, there is evidence that genetic polymorphisms in the caveolin 1–caveolin 2 intergenic region are associated with POAG. Caveolin is biophysically partitioned with NOS3 in all biologic membranes that undergo endocytosis and serves to negatively regulate NOS3 activity. Caveolin participates in many biologic processes, including the transcytosis of aqueous humor in the TM. Thus, NO appears to be an attractive therapeutic target in glaucoma.

Dr Buys: Vascular dysfunction in patients with POAG is likely due, at least in part, to impaired NO signaling, as opposed to dysfunction of other vasoreactive signaling mechanisms. However, from a practical perspective, the underlying mechanism causing the dysfunction may be

increase in forearm blood flow was markedly attenuated in patients with untreated normal-tension glaucoma compared with controls.³³ Likewise, peripheral limb ischemia should induce brachial artery vasodilation, but this response is impaired in patients with open-angle glaucoma across the spectrum of IOP.³⁴ These studies suggest an underlying impairment of the NO pathway in these patients.

NITRIC OXIDE PATHWAY AS A THERAPEUTIC TARGET IN GLAUCOMA

In light of the data supporting the role of impaired NO signaling in open-angle glaucoma, it is reasonable to investigate potential therapeutic targets within the NO signaling pathway that might prove effective in the

less important than the fact that NO can rescue the dysfunction, regardless of which pathway is perturbed.

Q: Where might NO-donating IOP-lowering drugs fit into the current treatment regimen? Is there a particular patient subgroup in which this approach may be most beneficial?

Dr Pasquale: Drugs such as latanoprostene bunod (LBN) seem appropriate for patients who have not achieved target IOP or who are showing signs of progression on prostaglandin analogue alone or prostaglandin analogue used in combination with other agents.

Dr Weinreb: The additional IOP lowering achieved with LBN vs latanoprost, 0.005%, in the phase 2 clinical trial suggests that LBN may be appropriate in any patient with POAG being treated with latanoprost in whom additional IOP lowering is needed.

Dr Kaufman: I see a potential role for this drug in 3 distinct patient subgroups: (1) patients who can manage only 1 topical medication once daily and cannot use a beta-blocker for whatever reason; (2) patients for whom a prostaglandin analogue and a beta-blocker are not enough, but we do not think adding another aqueous flow suppressant will contribute anything; and (3) patients not achieving target pressure on their current regimen.

Q: Given that NO might also be beneficial for optic nerve head blood flow, what are the opportunities and challenges for developing an NO-based therapy targeted at the optic nerve head?

treatment of glaucoma. The NO pathway represents a novel therapeutic target for glaucoma, and an NO-based therapy would offer a unique mechanism of action among existing treatment options. Multiple potential approaches are currently being investigated. Among these, agonists of sGC are being evaluated to increase production of cGMP, which results in vasodilation and increased outflow facility.^{35,36} Dietary supplementation with L-arginine represents a potential upstream intervention for conditions associated with NO pathway impairment. Such an approach may have value in favorably modulating endothelial dysfunction associated with diabetes, smoking, and obesity, although evidence to date is limited to animal and early clinical studies.⁶ An analysis of the Nurses' Health Study and

Dr Pasquale: First, we need to demonstrate that topically applied NO-donating drugs reach the retina surface at a concentration that achieves retinal vascular reactivity. Perhaps this type of research can be performed in animals and ex vivo preparations of retinal vascular tissues. Further, if disc hemorrhages are really a manifestation of impaired retinal vascular regulation, and assuming that an NO-donating therapy may enhance retinal vascular NO signaling, then it will be interesting to see if a drug like LBN reduces the frequency of disc hemorrhages, a biomarker that is highly correlated with disease progression.

Dr Buys: Because NO will not preferentially increase optic nerve head blood flow, but blood flow to any vascular tissue that the NO donor reaches, one would have to consider ocular hyperemia as a possible side effect, particularly with topically applied therapies.

Dr Stamer: Given potential issues, such as ocular penetration and topical side effects, we may need to develop a novel drug or delivery method to optimize the balance between efficacy and safety.

Dr Weinreb: One needs to know whether the NO from the topical medication is achieving biologically active levels at the retina and optic nerve head. One also needs to know that there is optic nerve (and retina) vasodilation, and that the vasodilation is beneficial to the disease outcome. This would require a clinical trial that would follow disease markers (eg, visual fields and retinal nerve fiber layer thickness) over time.

Dr Kaufman: These are all excellent points. However, there remains the need for further research to establish both that NO-donating compounds, such as LBN, do have effects on optic nerve head blood flow and that such effects are clinically beneficial in glaucoma.

Q: Should we be encouraging our patients with glaucoma to consume more nitrate-rich diets?

Dr Pasquale: Certainly nitrates derived from green-leafy vegetables have no downsides and have much in the way of potential health benefits. The reason it might be helpful in POAG is because of the nitrate-nitrite-NO cycle. Vegetable-derived nitrates are safely converted to NO via this pathway and serve as an exogenous source of NO. Theoretically, such a source of NO can be readily delivered to the TM and optic nerve. Our research showed that dietary nitrates from green-leafy vegetables were associated with a reduced risk of incident POAG, especially for cases with early paracentral visual loss. We think the latter finding is interesting because patients with impaired NO signaling may be particularly prone to paracentral vision loss. Our results were consistent with those of the Study of Osteoporotic Fractures, in which > 1 serving of kale or collard greens per week was associated with a reduced risk of glaucoma.¹ Of course, these are observational studies and not randomized clinical trials. More study is needed to prove that consuming more nitrates from vegetable sources benefits patients with glaucoma.

1. Giacony JA, Yu F, Stone KL, et al; Study of Osteoporotic Fractures Research Group. The association of consumption of fruits/vegetables with decreased risk of glaucoma among older African-American women in the study of osteoporotic fractures. *Am J Ophthalmol*. 2012;154(4):635-644.

Health Professionals Follow-up Study suggests that higher dietary nitrate intake may be related to a lower incidence of POAG,³⁷ especially the subtype categorized by early paracentral visual field loss.

An alternate approach is to increase intraocular NO directly, for example, via NO donor compounds. One such compound is nipradilol, an adrenergic receptor antagonist with an NO-donating moiety. Nipradilol is approved in Japan for the reduction of IOP in patients with glaucoma.¹⁸ Nipradilol is neuroprotective in animal models of glaucoma,³⁸⁻⁴⁰ and was the subject of a human clinical trial in Japan to evaluate its ability to confer neuroprotection in normal-tension glaucoma.⁴¹ In this study, patients with normal-tension

glaucoma randomly received either timolol, 0.5%, or topical nipradilol, 0.25%, twice daily for 36 months. These drugs are known to provide comparable IOP reduction.⁴² The primary end point was visual field progression, with a hypothesis that if nipradilol provides neuroprotection in addition to IOP reduction, then visual field progression should be less in the nipradilol group than in the timolol group.⁴¹ Both drugs lowered IOP comparably, with similar overall rates of visual field progression. However, a subsequent subgroup analysis revealed a statistical advantage of nipradilol over timolol in visual field progression, as measured by the corrected pattern standard deviation and by the average total deviation in the superior central subfield of the visual field ($P \leq .001$).⁴³ Adverse

events were similar in nature and frequency in both groups and included blepharitis, keratitis, ocular hyperemia, and conjunctivitis.⁴¹ In a separate study, topical nipradilol was shown to improve optic nerve head blood flow.⁴⁴ Taken together, these results suggest neuroprotection as an additional mechanism of action beyond IOP reduction for nipradilol in human glaucoma, although additional research is needed to explore these preliminary observations more fully.

Latanoprostene bunod is another NO-donating drug and prodrug that is metabolized to latanoprost and an NO molecule by ocular esterase enzymes.¹⁹ Preclinical studies evaluated the effects of LBN vs latanoprost alone on human TM cell contractility and the NO-cGMP signaling pathway.⁴⁵ In these studies, LBN significantly increased cGMP levels and reduced TM cell contractility compared with latanoprost. In a nonhuman primate model of glaucoma, LBN lowered IOP more than an equimolar dose of latanoprost did (35% and 25%, respectively).⁴⁶

In a phase 2 study, LBN provided an approximately 1- to 1.5-mm Hg greater IOP reduction than did latanoprost ($P \leq .009$).⁴⁷ Results from a phase 3 clinical trial of LBN have been reported recently.⁴⁸ In this randomized, multicenter, double-masked study, 420 patients with either ocular hypertension or POAG were randomized to receive either LBN, 0.024%, every evening or timolol, 0.5%, twice daily for 3 months. The primary outcome measure was postbaseline IOP measured at 8 AM, 12 PM, and 4 PM at weeks 2 and 6 and month 3. The mean IOP at all 9 time points was significantly lower with LBN than with timolol ($P \leq .002$). In this study, significantly more patients treated with LBN achieved an IOP of ≤ 18 mm Hg and a $\geq 25\%$ reduction in IOP than did those treated with timolol. The most common treatment-emergent adverse events were mild to moderate and included eye irritation upon instillation and conjunctival hyperemia, both of which were seen more frequently in the LBN group. There was 1 instance of severe eye pain in the timolol group. The investigators concluded that LBN, 0.024%, once daily was safe and effective, with significantly greater IOP-lowering effects than timolol. If LBN should garner approval by the US Food and Drug Administration, it would represent the first new drug with a novel mechanism of action since the debut of latanoprost in the mid-1990s.

Other well-established IOP-lowering agents are under investigation as potential NO donors. For example, an NO-donating formulation of bimatoprost is currently in development. In various animal models of glaucoma, this formulation produced mean IOP reductions on the order of 5 to 8 mm Hg in rabbits, dogs, and monkeys, in each case in excess of bimatoprost alone.⁴⁹ Similarly, NO-donating formulations of the carbonic anhydrase inhibitors dorzolamide and brinzolamide lowered IOP in animal models more effectively than did the isolated carbonic anhydrase inhibitor molecules alone.⁵⁰

CONCLUSION

Glaucoma is a multifactorial disease with a complex pathophysiology and many known risk factors. Reduction of IOP remains the only established therapy. Intraocular pressure regulation is incompletely understood and involves many diverse physiologic pathways. A better understanding of the NO-cGMP pathway in human health and disease has resulted in novel therapeutic targets for many disease states, including glaucoma. The NO-cGMP pathway plays a role in the regulation of both optic nerve head blood flow and IOP, both of which are critically important in the glaucomatous disease state. The NO-donating molecule nipradilol, approved in Japan for the treatment of glaucoma, provides a proof of concept for this novel class of medications. The NO donor LBN shows significant promise as a novel therapeutic agent for glaucoma. Latanoprostene bunod and other emerging drugs have the potential to alter clinical glaucoma management in the near future, providing ever more tools to enhance the individualization of glaucoma therapy for our patients.

REFERENCES

1. Steinhorn BS, Loscalzo J, Michel T. Nitroglycerin and nitric oxide—a rondo of themes in cardiovascular therapeutics. *N Engl J Med*. 2015;373(3):277-280.
2. Arnold WP, Mittal CK, Katsuki S, Murad F. Nitric oxide activates guanylate cyclase and increases guanosine 3':5'-cyclic monophosphate levels in various tissue preparations. *Proc Natl Acad Sci U S A*. 1977;74(8):3203-3207.
3. Katsuki S, Arnold W, Mittal C, Murad F. Stimulation of guanylate cyclase by sodium nitroprusside, nitroglycerin and nitric oxide in various tissue preparations and comparison to the effects of sodium azide and hydroxylamine. *J Cyclic Nucleotide Res*. 1977;3(1):23-35.
4. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. *Nature*. 1987;327(6122):524-526.
5. Koshland DE Jr. The molecule of the year. *Science*. 1992;258(5090):1861.
6. Murad F. Shattuck Lecture. Nitric oxide and cyclic GMP in cell signaling and drug development. *N Engl J Med*. 2006;355(19):2003-2011.
7. Huang SA, Lie JD. Phosphodiesterase-5 (PDE5) inhibitors in the management of erectile dysfunction. *P T*. 2013;38(7):407-419.
8. Spina D. PDE4 inhibitors: current status. *Br J Pharmacol*. 2008;155(3):308-315.
9. Hoepfer MM, McLaughlin VV, Dalaan AM, Satoh T, Galiè N. Treatment of pulmonary hypertension [published online ahead of print March 11, 2016]. *Lancet Respir Med*. doi:10.1016/S2213-2600(15)00542-1.
10. Papapetropoulos A, Hobbs AJ, Topouzis S. Extending the translational potential of targeting NO/cGMP-regulated pathways in the CVS. *Br J Pharmacol*. 2015;172(6):1397-1414.
11. Haeffliger IO, Flammer J, Bény JL, Lüscher TF. Endothelium-dependent vasoactive modulation in the ophthalmic circulation. *Prog Retin Eye Res*. 2001;20(2):209-225.
12. Adachi K, Fujita Y, Morizane C, et al. Inhibition of NMDA receptors and nitric oxide synthase reduces ischemic injury of the retina. *Eur J Pharmacol*. 1998;350(1):53-57.
13. Geyer O, Almog J, Lupu-Meiri M, Lazar M, Oron Y. Nitric oxide synthase inhibitors protect rat retina against ischemic injury. *FEBS Lett*. 1995;374(3):399-402.
14. Wiederholt M, Thieme H, Stumpff F. The regulation of trabecular meshwork and ciliary muscle contractility. *Prog Retin Eye Res*. 2000;19(3):271-295.
15. Becquet F, Courtois Y, Goureau O. Nitric oxide in the eye: multifaceted roles and diverse outcomes. *Surv Ophthalmol*. 1997;42(1):71-82.
16. Nathanson JA, McKee M. Identification of an extensive system of nitric oxide-producing cells in the ciliary muscle and outflow pathway of the human eye. *Invest Ophthalmol Vis Sci*. 1995;36(9):1765-1773.
17. Dismuke WM, Mbadugha CC, Ellis DZ. NO-induced regulation of trabecular meshwork cell volume and aqueous humor outflow facility involve the BK_{Ca} ion channel. *Am J Physiol Cell Physiol*. 2008;294(6):C1378-C1386.
18. Cavet ME, Vittitow JL, Impagnatiello F, Ongini E, Bastia E. Nitric oxide (NO): an emerging target for the treatment of glaucoma. *Invest Ophthalmol Vis Sci*. 2014;55(8):5005-5015.
19. Kee C, Kaufman PL, Gabelt BT. Effect of 8-Br cGMP on aqueous humor dynamics in monkeys. *Invest Ophthalmol Vis Sci*. 1994;35(6):2769-2773.
20. Stamer WD, Lei Y, Boussommier-Calleja A, Overby DR, Ethier CR. eNOS, a pressure-dependent regulator of intraocular pressure. *Invest Ophthalmol Vis Sci*. 2011;52(13):9438-9444.
21. Lei Y, Zhang X, Song M, Wu J, Sun X. Aqueous humor outflow physiology in NOS3 knockout mice. *Invest Ophthalmol Vis Sci*. 2015;56(8):4891-4898.
22. Buys ES, Ko YC, Alt C, et al. Soluble guanylate cyclase $\alpha 1$ -deficient mice: a novel murine model for primary open angle glaucoma. *PLoS One*. 2013;8(3):e60156.
23. Dismuke WM, Liang J, Overby DR, Stamer WD. Concentration-related effects of nitric oxide and endothelin-1 on human trabecular meshwork cell contractility. *Exp Eye Res*. 2014;120:28-35.
24. Chang JY, Stamer WD, Bertrand J, et al. Role of nitric oxide in murine conventional outflow physiology. *Am J Physiol Cell Physiol*. 2015;309(4):C205-C214.
25. Polak K, Luksch A, Berisha F, Fuchsjaeger-Mayrl G, Dallinger S, Schmetterer L. Altered nitric oxide system in patients with open-angle glaucoma. *Arch Ophthalmol*. 2007;125(4):494-498.
26. Hannappel E, Pankow G, Grassl F, Brand K, Naumann GO. Amino acid pattern in human aqueous humor of patients with senile cataract and primary open-angle glaucoma. *Ophthalmic Res*. 1985;17(6):341-343.
27. Carter-Dawson L, Crawford ML, Harwerth RS, et al. Vitreal glutamate concentration in monkeys with experimental glaucoma. *Invest Ophthalmol Vis Sci*. 2002;43(8):2633-2637.
28. Galassi F, Renieri G, Sodi A, Ucci F, Vannozzi L, Masini E. Nitric oxide proxies and ocular perfusion pressure in primary open angle glaucoma. *Br J Ophthalmol*. 2004;88(6):757-760.

29. Doganay S, Evereklioglu C, Turkoz Y, Er H. Decreased nitric oxide production in primary open-angle glaucoma. *Eur J Ophthalmol*. 2002;12(1):44-48.
30. Kang JH, Wiggs JL, Rosner BA, et al. Endothelial nitric oxide synthase gene variants and primary open-angle glaucoma: interactions with sex and postmenopausal hormone use. *Invest Ophthalmol Vis Sci*. 2010;51(2):971-979.
31. Magalhães da Silva T, Rocha AV, Lacchini R, et al. Association of polymorphisms of endothelial nitric oxide synthase (eNOS) gene with the risk of primary open angle glaucoma in a Brazilian population. *Gene*. 2012;502(2):142-146.
32. Xiang Y, Dong Y, Li X, Tang X. Association of common variants in eNOS gene with primary open angle glaucoma: a meta-analysis. *J Ophthalmol*. 2016;2016:1348347.
33. Henry E, Newby DE, Webb DJ, O'Brien C. Peripheral endothelial dysfunction in normal pressure glaucoma. *Invest Ophthalmol Vis Sci*. 1999;40(8):1710-1714.
34. Su WW, Cheng ST, Ho WJ, Tsay PK, Wu SC, Chang SH. Glaucoma is associated with peripheral vascular endothelial dysfunction. *Ophthalmology*. 2008;115(7):1173-1178.e1.
35. Buys ES, Potter LR, Pasquale LR, Ksander BR. Regulation of intraocular pressure by soluble and membrane guanylate cyclases and their role in glaucoma. *Front Mol Neurosci*. 2014;7:38.
36. Ge P, Navarro ID, Kessler MM, et al. The soluble guanylate cyclase stimulator IWP-953 increases conventional outflow facility in mouse eyes. *Invest Ophthalmol Vis Sci*. 2016;57(3):1317-1326.
37. Kang JH, Willett WC, Rosner BA, Buys E, Wiggs JL, Pasquale LR. Association of dietary nitrate intake with primary open-angle glaucoma: a prospective analysis from the Nurses' Health Study and Health Professionals Follow-up Study. *JAMA Ophthalmol*. 2016;134(3):294-303.
38. Karim MZ, Sawada A, Mizuno K, Kawakami H, Ishida K, Yamamoto T. Neuroprotective effect of nipradilol [3,4-dihydro-8-(2-hydroxy-3-isopropylamino)-propoxy-3-nitroxy-2H-1-benzopyran] in a rat model of optic nerve degeneration. *J Glaucoma*. 2009;18(1):26-31.
39. Mizuno K, Koide T, Yoshimura M, Araie M. Neuroprotective effect and intraocular penetration of nipradilol, a beta-blocker with nitric oxide donative action. *Invest Ophthalmol Vis Sci*. 2001;42(3):688-694.
40. Watanabe M, Tokita Y, Yata T. Axonal regeneration of cat retinal ganglion cells is promoted by nipradilol, an anti-glaucoma drug. *Neuroscience*. 2006;140(2):517-528.
41. Araie M, Shirato S, Yamazaki Y, Kitazawa Y, Ohashi Y; Nipradilol-Timolol Study Group. Clinical efficacy of topical nipradilol and timolol on visual field performance in normal-tension glaucoma: a multicenter, randomized, double-masked comparative study. *Jpn J Ophthalmol*. 2008;52(4):255-264.
42. Kanno M, Araie M, Masuda K, et al. Phase III long-term study and comparative clinical study of nipradilol ophthalmic solution in patients with primary open-angle glaucoma and ocular hypertension. Part 2. *Arzneimittelforschung*. 2006;56(12):820-825.
43. Araie M, Shirato S, Yamazaki Y, Kitazawa Y, Ohashi Y; Nipradilol-Timolol Study Group. Visual field loss in patients with normal-tension glaucoma under topical nipradilol or timolol: subgroup and subfield analyses of the nipradilol-timolol study. *Jpn J Ophthalmol*. 2010;54(4):278-285.
44. Fukukita M, Ido M, Osawa S, et al. Retrobulbar hemodynamic effects of nipradilol in normal and normal-tension glaucoma eyes. *J Ophthalmol*. 2011;2011:652904.
45. Cavet ME, Vollmer TR, Harrington KL, VanDerMeid K, Richardson ME. Regulation of endothelin-1-induced trabecular meshwork cell contractility by latanoprostene bunod. *Invest Ophthalmol Vis Sci*. 2015;56(6):4108-4116.
46. Krauss AH, Impagnatiello F, Toris CB, et al. Ocular hypotensive activity of BOL-303259-X, a nitric oxide donating prostaglandin F2 α agonist, in preclinical models. *Exp Eye Res*. 2011;93(3):250-255.
47. Weinreb RN, Ong T, Scassellati Sforzolini B, Vittitow JL, Singh K, Kaufman PL; VOYAGER Study Group. A randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open angle glaucoma: the VOYAGER study. *Br J Ophthalmol*. 2015;99(6):738-745.
48. Weinreb RN, Scassellati Sforzolini B, Vittitow J, Liebmann J. Latanoprostene bunod 0.024% versus timolol maleate 0.5% in subjects with open-angle glaucoma or ocular hypertension: the APOLLO Study. *Ophthalmology*. 2016;123(5):965-973.
49. Impagnatiello F, Toris CB, Batugo M, et al. Intraocular pressure-lowering activity of NCX 470, a novel nitric oxide-donating bimatoprost in preclinical models. *Invest Ophthalmol Vis Sci*. 2015;56(11):6558-6564.
50. Huang Q, Rui EY, Cobbs M, et al. Design, synthesis, and evaluation of NO-donor containing carbonic anhydrase inhibitors to lower intraocular pressure. *J Med Chem*. 2015;58(6):2821-2833.



CME POST TEST QUESTIONS

To obtain *AMA PRA Category 1 Credit™* for this activity, complete the CME Post Test by writing the best answer to each question in the Answer Box located on the Activity Evaluation/Credit Request form on the following page. Alternatively, you can complete the CME Post Test at <http://tinyurl.com/nitricoxidelOP>.

See detailed instructions under **To Obtain AMA PRA Category 1 Credit™** on page 2.

1. One of the first diseases in which NO served as a therapeutic target was:
 - a. Cancer
 - b. Angina pectoris
 - c. Cerebrovascular accidents
 - d. Multiple sclerosis
2. Nitric oxide's physiologic effect results in:
 - a. Tachycardia
 - b. Lipid metabolism
 - c. Smooth muscle relaxation
 - d. Norepinephrine reuptake
3. Patients with POAG might exhibit which of the following abnormalities?
 - a. Increased aqueous humor level of cGMP
 - b. Enhanced vasodilatory response to intravenous ACh
 - c. Failure of vasodilation to peripheral limb ischemia
 - d. All the above
4. Nitric oxide lowers IOP by which of the following mechanisms?
 - a. Decreasing episcleral venous pressure
 - b. Decreasing aqueous fluid production
 - c. Increasing uveoscleral outflow
 - d. Increasing trabecular outflow
5. Which of the following ocular structures is NOT relevant to the trabecular outflow pathway?
 - a. Juxtacanalicular TM
 - b. Schlemm canal
 - c. Corneal endothelium
 - d. Episcleral blood vessels
6. A phase 3 trial compared an NO-donating formulation of latanoprost, LBN, with timolol. Which of the following is FALSE regarding this trial?
 - a. The patient population included patients with ocular hypertension and glaucoma
 - b. The mean IOP at all 9 time points was lower with LBN than with timolol, but the results were not statistically significant
 - c. More patients treated with LBN achieved an IOP of ≤ 18 mm Hg and a $\geq 25\%$ reduction in IOP than did those treated with timolol
 - d. The most common treatment-emergent adverse events were mild to moderate and included eye pain upon instillation in both treatment groups, with 1 case of severe eye pain in the timolol group
7. Which of the following regarding dietary nitrates is FALSE?
 - a. They are found in green-leafy vegetables
 - b. They have many systemic health benefits
 - c. Epidemiologic studies suggest that a nitrate-rich diet may be associated with a reduced risk of incident POAG
 - d. One serving of kale or collards per month can lower IOP

ACTIVITY EVALUATION/CREDIT REQUEST**THE ROLE OF NITRIC OXIDE IN GLAUCOMA**

To receive *AMA PRA Category 1 Credit™*, you must complete this **Evaluation** form and the **Post Test**. Record your answers to the **Post Test** in the Answer Box located below. Mail or Fax this completed page to **New York Eye and Ear Infirmary of Mount Sinai–ICME**, 310 East 14th Street, New York, NY 10003 (Fax: 212-353-5703). Your comments help us to determine the extent to which this educational activity has met its stated objectives, assess future educational needs, and create timely and pertinent future activities. Please provide all the requested information below. This ensures that your certificate is filled out correctly and is mailed to the proper address. It also enables us to contact you about future CME activities. Please print clearly or type. Illegible submissions cannot be processed.

PARTICIPANT INFORMATION (Please Print) ☐ Home ☐ Office

Last Name _____ First Name _____

Specialty _____ Degree ☐ MD ☐ DO ☐ OD ☐ PharmD ☐ RPh ☐ NP ☐ RN ☐ PA ☐ Other _____

Institution _____

Street Address _____

City _____ State _____ ZIP Code _____ Country _____

E-mail _____ Phone _____ Fax _____

Please note: We do not sell or share e-mail addresses. They are used strictly for conducting post-activity follow-up surveys to assess the impact of this educational activity on your practice.

Learner Disclosure: To ensure compliance with the US Centers for Medicare and Medicaid Services regarding gifts to physicians, **New York Eye and Ear Infirmary of Mount Sinai** Institute for CME requires that you disclose whether or not you have any financial, referral, and/or other relationship with our institution. **CME certificates cannot be awarded unless you answer this question.** For additional information, please call NYEE ICME at 212-979-4383. Thank you.

☐ Yes ☐ No I and/or my family member have a financial relationship with **New York Eye and Ear Infirmary of Mount Sinai** and/or refer Medicare/Medicaid patients to it.

☐ I certify that I have participated in the entire activity and claim 1.5 *AMA PRA Category 1 Credits™*.

Signature Required _____ Date Completed _____

OUTCOMES MEASUREMENT

☐ Yes ☐ No **Did you perceive any commercial bias in any part of this activity? IMPORTANT! If you answered “Yes,” we urge you to be specific about where the bias occurred so we can address the perceived bias with the contributor and/or in the subject matter in future activities.**

Circle the number that best reflects your opinion on the degree to which the following learning objectives were met:

5 = Strongly Agree 4 = Agree 3 = Neutral 2 = Disagree 1 = Strongly Disagree

Upon completion of this activity, I am better able to:

- | | | | | | |
|---|---|---|---|---|---|
| • Correlate the pathophysiologic factors contributing to glaucoma with sites of action for available treatments | 5 | 4 | 3 | 2 | 1 |
| • Discuss the role of nitric oxide in IOP regulation | 5 | 4 | 3 | 2 | 1 |
| • Describe the potential role of nitric oxide–based emerging therapeutics in the management of glaucoma | 5 | 4 | 3 | 2 | 1 |

1. Please list one or more things, if any, you learned from participating in this educational activity that you did not already know.

2. As a result of the knowledge gained in this educational activity, how likely are you to implement changes in your practice?

4 = definitely will implement changes 3 = likely will implement changes 2 = likely will not implement any changes 1 = definitely will not make any changes

4 3 2 1

Please describe the change(s) you plan to make: _____

3. Related to what you learned in this activity, what barriers to implementing these changes or achieving better patient outcomes do you face? _____

4. Please check the Core Competencies (as defined by the Accreditation Council for Graduate Medical Education) that were enhanced for you through participation in this activity.

- | | | |
|--|--|---|
| <input type="checkbox"/> Patient Care | <input type="checkbox"/> Practice-Based Learning and Improvement | <input type="checkbox"/> Professionalism |
| <input type="checkbox"/> Medical Knowledge | <input type="checkbox"/> Interpersonal and Communication Skills | <input type="checkbox"/> Systems-Based Practice |

5. What other topics would you like to see covered in future CME programs? _____

ADDITIONAL COMMENTS _____

POST TEST ANSWER BOX

1	2	3	4	5	6	7